Fifty scientists from sixteen countries published a warning in Nature Medicine this week: drug-resistant fungi are spreading silently from farms to hospitals, threatening patients with weakened immune systems.
The group, led by Paul Verweij of Radboud University Medical Center in the Netherlands, says resistance is growing most dramatically in Candida auris and Aspergillus fumigatus, two fungi that can cause deadly bloodstream and lung infections. Invasive fungal diseases affect over 6.5 million people globally each year, and mortality remains high even when drugs work—now, rising resistance is making treatment harder.
What alarms experts most is the origin of this resistance: not in hospitals, but in agricultural fields where fungicides chemically similar to medical antifungals are used on crops like wheat, maize, and watermelons. Long-term exposure allows fungi in soil and plant matter to develop resistance, which then spreads via airborne spores that can travel continents on jet streams before being inhaled by humans.
How agricultural fungicides are driving medical drug resistance
The same chemical mechanisms that protect crops are undermining patient care. Fungicides used in agriculture belong to the azole class, which mirrors the antifungal drugs doctors rely on to treat infections like candidiasis and aspergillosis. When fungi in fields are repeatedly exposed to these compounds, they evolve resistance—not just to the farm chemicals, but to the medical drugs as well.
This cross-resistance is unintended but well-documented. The fungi causing human infections don’t infect plants, yet they share enough biological similarity that agricultural pressure selects for traits that defeat clinical treatments. Verweij calls this a “silent surge” because it happens without routine monitoring, especially in low- and middle-income countries where diagnostic capacity is limited.
In places without advanced lab testing, a patient may die of a fungal infection without clinicians ever knowing it was drug-resistant—or even fungal in origin. “People will die, and you won’t know they have a fungal infection,” Verweij said in an interview with NPR. “You wouldn’t know if it was resistant.”
For more on this story, see Global Experts Call for Urgent Action Against Drug-Resistant Fungi.
Why current global health plans overlook fungal threats
For decades, the World Health Organization’s Global Action Plan on Antimicrobial Resistance has focused almost exclusively on bacteria and viruses. Fungal pathogens were largely absent from strategy documents, funding priorities, and surveillance networks—despite causing millions of infections annually.
The researchers’ five-step plan, published alongside their warning, seeks to change that. It calls for raising awareness, expanding surveillance, strengthening infection prevention in hospitals, optimizing existing antifungal leverage, and investing in recent diagnostics and medicines—with emphasis on technology transfer and local manufacturing in low-resource settings.
They urge that antifungal resistance be integrated into the upcoming 2026 update of the WHO’s Global Action Plan, with concrete milestones and funding. Without it, Verweij warns, the world risks repeating the oversight that allowed antibacterial resistance to escalate unchecked for years.
What makes new antifungal drugs so tricky to develop
Unlike bacteria, fungal cells share fundamental biological machinery with human cells—making it hard to design drugs that kill the pathogen without harming the patient. This similarity increases the risk of toxic side effects, which has discouraged pharmaceutical investment and slowed the pipeline of new antifungals.
This follows our earlier report, The Rise of Multi-Resistant Bacteria: The Growing Threat in Munich Hospitals.
clinicians rely on aging drug classes, increasing pressure to preserve their effectiveness. Yet without new options, and with resistance spreading from environments never intended to be part of the medical equation, the therapeutic window is narrowing.
How do fungi develop resistance if they don’t infect plants?
Resistance develops in environmental fungi—like those in soil or on plant surfaces—that are exposed to agricultural fungicides. These fungi don’t cause human disease, but they can pass resistance genes to pathogenic species through horizontal gene transfer, or the resistant strains themselves can evolve traits that affect medical drugs due to shared biological targets.
Why is Candida auris particularly dangerous in hospitals?
Candida auris can survive on surfaces for weeks, resist standard cleaning agents, and spread silently between patients. It causes invasive bloodstream infections in vulnerable individuals, and roughly one in three infected patients dies—often before resistance is even detected due to limited diagnostic access in many facilities.
